The data underlying the results presented in the study are from individual studies whose authors collaborated in this meta-analysis. If access to the data is sought, this should be requested from the principal investigators/corresponding authors of the individual studies.

Introduction {#sec007}
============

The role of opportunistic or systematic atrial fibrillation (AF) screening for people aged ≥65 years remains contested, with variation in recommendations between international AF clinical guidelines. However, 10% of all ischaemic strokes are in individuals with undiagnosed AF \[[@pmed.1002903.ref001]\], and early identification of AF and appropriate guideline-based oral anticoagulation (OAC) treatment can prevent strokes and thus reduce health costs related to AF \[[@pmed.1002903.ref002]\]. Organisations supporting the recommendation to screen include the European Society of Cardiology (ESC) \[[@pmed.1002903.ref003]\], the European Heart Rhythm Association \[[@pmed.1002903.ref004]\], the Royal College of Physicians of Edinburgh \[[@pmed.1002903.ref005]\], AF-SCREEN International Collaboration \[[@pmed.1002903.ref006]\], and, recently, the Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand \[[@pmed.1002903.ref007]\].

The evidence to support screening has mainly been extrapolated from studies of people with clinically or incidentally diagnosed AF and from prevalence studies that show both AF prevalence and stroke risk increase substantially from age 65. No large outcome trial of screen-detected AF using hard events, including stroke and death, has been reported to date. Few studies have reported the baseline estimated stroke risk of screen-detected AF patients. In the screening for atrial fibrillation in the elderly (SAFE) trial, the calculated stroke risk was the same in screen-detected and symptomatically identified AF patients \[[@pmed.1002903.ref008]\], but it was not possible to accurately determine the stroke risk in discrete age strata or the number needed to screen (NNS) to identify one treatable new AF case (NNS-Rx) in each age stratum. This information is important for precise cost-effectiveness and sensitivity simulations based on the age distribution of the population to be screened. Such calculations are required by payers to determine the best age cutoffs for screening programs and decide whether programs of screening should be funded.

We therefore performed a systematic review and meta-analysis to investigate the yield of new AF identified in contemporary AF screening studies (single time point) and to explore the stroke risk profile and OAC eligibility of those identified, in order to determine the precise age distribution and calculated stroke risk of AF in 5-year age strata to enable accurate cost-effectiveness modelling.

Methods {#sec008}
=======

This systematic review and patient-level meta-analysis was performed in accordance with the preferred reporting items for systematic reviews and meta-analysis ([S1 PRISMA checklist](#pmed.1002903.s001){ref-type="supplementary-material"}) and the meta-analyses of observational studies in epidemiology guidelines \[[@pmed.1002903.ref009],[@pmed.1002903.ref010]\]. All collaborating studies had ethical approval for their study, the details of which are reported in the individual study manuscripts \[[@pmed.1002903.ref011]--[@pmed.1002903.ref029]\]. Ethical approval was not required for this collaborative secondary analysis of data.

Search strategy and selection criteria {#sec009}
--------------------------------------

Relevant studies were identified by two independent reviewers (NL and BF) through electronic database searching of MEDLINE, Pubmed, Embase, and Google. The keyword search terms used were as follows: atrial fibrillation AND \[screening OR incidence OR prevalence OR detection OR identification\] up to February 2018. To ensure a relevant contemporary sample was obtained, limits were applied to years 2007 onwards, and human research. Studies published in any language were permitted. Additional studies were identified through directly contacting members of the AF-SCREEN International Collaboration \[[@pmed.1002903.ref006]\]. Study authors from all eligible studies were contacted via email, with an explanation of the proposed study and an invitation to collaborate.

The inclusion criteria for screening studies were as follows: (i) evaluated a general ambulant population; (ii) included people ≥65 years within their screened population; (iii) used a valid method to identify AF, as accepted by the ESC 2016 AF guidelines (i.e., pulse palpation, 12-lead electrocardiogram \[ECG\], or ECG rhythm strip, with a validated device) \[[@pmed.1002903.ref003]\]; (iv) assessed the rate of newly identified AF using a single time point screen; (v) distinguished between newly identified AF and previously diagnosed AF; (vi) screened a sample size of at least 1,000 people; (vii) collected participant age and gender for all new AF; and (viii) collected participant age for all participants screened. Studies were excluded if they performed repeated, intermittent, or continuous recordings over a period to identify unknown AF or if screening was targeted at a specific subgroup (e.g., limited age range, hypertension, diabetes, poststroke).

Assessment of Quality of Reporting was not performed, as some participating studies had not published their results. However, to ensure only studies of appropriate quality were included, our study inclusion criteria were intentionally developed based on the modified Newcastle-Ottawa scale criteria, specifically (i) the source population is representative, (ii) past history of AF is ascertained, (iii) a validated measurement tool is used, (iv) sample size is adequate, (v) methodology is appropriate for outcomes, and (vi) variables are clearly defined.

Study outcomes {#sec010}
--------------

The primary study outcome was the detection rate for cases of new AF identified through screening of people aged ≥65 years with one screen at a single time point (reported as \[number of positive cases/100 persons screened\] and 95% CI). Secondary outcomes of interest were (i) detection rate for cases of new AF identified through screening with one screen at a single time point, stratified according to each age group (\<60, 60--64, 65--69, 70--74, 75--79, 80--84, and ≥85 years) (reported as \[number of positive cases/100 persons screened\] and 95% CI); (ii) CHA~2~DS~2~-VASc stroke risk score, stratified according to age group (reported as means and 95% CI); (iii) eligibility for OAC according to ESC 2016 guidelines, stratified according to age group (reported as number and percentage); (iv) proportion of new AF cases with stroke risk factors other than age and sex (i.e., chronic heart failure, hypertension, diabetes, prior stroke or transient ischaemic attack, or vascular disease), stratified according to age group (reported as number and percentage); (v) NNS to identify 1 new AF case for age ≥65 years, stratified according to age group; and (vi) NNS-Rx (i.e., new AF with a Class-1 recommendation to prescribe OAC) for age ≥65 years, stratified according to age group.

Statistical analysis {#sec011}
--------------------

Data from each study were exported into Microsoft Excel (version 1802) and checked for errors. Data fields collected from each study are summarised in [S1 Text](#pmed.1002903.s002){ref-type="supplementary-material"}. Descriptive analyses were carried out to describe characteristics of participating studies, total numbers screened, and total numbers of AF identified through screening, stratified according to age group and sex.

### Detection rate of new AF {#sec012}

The number of new AF cases among those screened was assumed to follow a binomial distribution, as only a binary outcome was possible from screening each participant (AF positive or AF negative). In accordance with our statistical analysis plan, the detection rate of new AF cases was estimated by random effects logistic regression. As binary data are unlikely to have a 'normal distribution', random effects logistic regression is preferred over conventional meta-analysis approaches that assume study-level effect sizes are normally distributed \[[@pmed.1002903.ref030]\]. The consequence of choosing this approach is that the standard meta-analytic methods for detecting heterogeneity and publication bias cannot be applied. Heterogeneity was therefore assessed using the study-level random effect and standard error.

Individual-level data were available for the screening outcome (AF positive or AF negative), sex, and age group. Study-level information was available for country, geographical region, urban/rural population, screening method/device, screening setting/design, era screened, and screening age eligibility. Due to the combination of both individual and study-level data, the individual-level data were modelled first, and then the study-level variables were added. Study was included as a random effect in all models.

For the individual-level data, three models were considered: the intercept only (overall mean), then the addition of age groups, and then gender. The appropriateness of including each variable was based on comparison of the Akaike information criterion for each model. The study-level covariates were then added to the model one at a time, and the Akaike information criterion was used to determine if they should be included or not, based on comparison to the Akaike information criterion of the final individual-level model.

Individual logistic regression models were used for study-level estimates, and summary estimates were computed from a random effects logistic regression model using SAS GLIMMIX (v9.4) while adjusted for covariates. Age group estimates were computed using least square means from the final random effects logistic regression model. The results of the analysis from SAS GLIMMIX were imported into R, and the metafor package (R 3.4.3 'Kite-Eating Tree') was used to create a forest plot. The results were reported for the age group ≥65 years and also stratified according to each age group (\<60, 60--64, 65--69, 70--74, 75--79, 80--84, ≥85 years).

### Stroke risk profile of new AF cases {#sec013}

Stroke risk of new AF cases was determined using the CHA~2~DS~2~-VASc score (range 0--9 points), which is the sum of risk factors: congestive heart failure/left ventricular dysfunction (1 point); high blood pressure (1 point); age \>75 years (2 points); diabetes (1 point); stroke/transient ischaemic attack/thromboembolism (2 points); vascular disease (coronary artery disease, myocardial infarction, peripheral artery disease, aortic plaque) (1 point); age 65--74 years (1 point); and sex category female (1 point). The CHA~2~DS~2~-VASc score was chosen to measure stroke risk as it is recommended by most international guidelines \[[@pmed.1002903.ref003],[@pmed.1002903.ref007],[@pmed.1002903.ref031]\], and it has demonstrated accuracy identifying AF patients who are at low risk of stroke and therefore do not require OAC \[[@pmed.1002903.ref032],[@pmed.1002903.ref033]\].

Random effects Poisson regression modelling was performed for the CHA~2~DS~2~-VASc score. As the maximum data value of the CHA~2~DS~2~-VASc score is 9, we modelled the Poisson mean for the data (1.04) and calculated the probability that the value could be larger than 9 (1.58 × 10^−7^) to ensure that truncation of data relative to the Poisson distribution was not an issue.

For Poisson regression with study as a random effect, age groups were included to stratify the CHA~2~DS~2~-VASc mean estimates according to age brackets. The study-level covariates (i.e., geographical region, country, rural/urban population) were then added to the model one at a time, and the Akaike information criterion was used to determine if they should be included or not, based on comparison to the Akaike information criterion of the individual-level model. The mean CHA~2~DS~2~-VASc scores were similar for each country, with one exception. The mean score for this country was 1.7 (CI 1.2--2.4), while the next lowest was 2.4 (CI 1.6--3.5). The inclusion of this country could unduly influence the overall summary estimates. To assess the impact of these data in a sensitivity analysis, the model was refit without data from this country, and the summary estimates were compared. The final model included data from all countries.

Guideline recommendations for OAC were calculated for each new AF case with CHA~2~DS~2~-VASc score and sex data. The ESC 2016 guidelines were used to classify OAC recommendations into (i) Class-1 OAC recommendation (CHA~2~DS~2~-VASc score: men ≥ 2; women ≥ 3), (ii) consider OAC (CHA~2~DS~2~-VASc score: men = 1; women = 2), or (iii) OAC not recommended (CHA~2~DS~2~-VASc score: men = 0; women = 1) \[[@pmed.1002903.ref003]\]. Data are reported as pooled number and percentages for each category and stratified according to age group (\<60, 60--64, 65--69, 70--74, 75--79, 80--84, ≥85 years).

The number of additional stroke risk factors other than age and sex were calculated for each person with new AF using the formula, CHA~2~DS~2~-VASc score − female sex point − age points, and reported as a pooled percentage of all new AF, stratified according to age group.

### NNS {#sec014}

The NNS to identify one new AF case was calculated using the inverse of the detection rate derived from the meta-regression, stratified according to age group. The NNS-Rx was calculated using the inverse of the determined yield of newly identified AF with a 2016 ESC Class-1 recommendation for OAC, stratified according to age group.

Results {#sec015}
=======

The search strategy identified 41 screening studies, of which 17 did not meet the eligibility criteria ([Fig 1](#pmed.1002903.g001){ref-type="fig"}). Study authors from the 24 eligible studies were contacted via email, and 19 studies \[[@pmed.1002903.ref011]--[@pmed.1002903.ref029]\] from 14 countries agreed to the collaboration and contributed screening data.

![Study selection.](pmed.1002903.g001){#pmed.1002903.g001}

A combined total of 141,220 participants were screened (approximately 44% men; sample size range, 1,000--59,505) ([Table 1](#pmed.1002903.t001){ref-type="table"}). Rates of detection of AF ranged from 0.35% in studies recruiting ≥40 years to 2.34% in studies recruiting ≥65 years. Studies recruited from community or population screening (*n* = 7), general practice (*n* = 6), outpatient clinics (*n* = 3), and pharmacies (*n* = 3). The screening methods used were single-lead ECG (*n* = 12), 12-lead ECG (*n* = 4), pulse palpation (*n* = 2), and modified blood pressure machine (*n* = 1).

10.1371/journal.pmed.1002903.t001

###### Characteristics of studies.

![](pmed.1002903.t001){#pmed.1002903.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, year                                                      Country,\                         Setting                Screening method                                                                                                                                                 Year screened   Age\           Number screened
                                                                    study name                                                                                                                                                                                                                                Eligibility\   
                                                                                                                                                                                                                                                                                                              (years)        
  ----------------------------------------------------------------- --------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- -------------- -----------------
  Proietti and colleagues, 2016 \[[@pmed.1002903.ref016]\]          Belgium,\                         Community/population   Single-lead ECG (Omron HCG-801)                                                                                                                                  2010--2014      ≥20            59,505
                                                                    Belgian Heart Rhythm Week                                                                                                                                                                                                                                

  Schnabel and colleagues, 2012 \[[@pmed.1002903.ref011]\]          Germany,\                         Community/population   12-lead ECG                                                                                                                                                      2007--2017      35--74         14,937
                                                                    Gutenberg Health Study                                                                                                                                                                                                                                   

  Yan and colleagues, 2017 \[[@pmed.1002903.ref012]\]               Hong Kong                         Outpatient clinic      Single-lead ECG (AliveCor)                                                                                                                                       2015--2017      ≥40            12,928

  Gomez-Doblas and colleagues, 2014 \[[@pmed.1002903.ref013]\]      Spain,\                           Community/population   12-lead ECG                                                                                                                                                      2010--2012      ≥40            8,396
                                                                    OFRECE                                                                                                                                                                                                                                                   

  Deif and colleagues, 2013 \[[@pmed.1002903.ref014]\]              Australia                         Outpatient clinic      12-lead ECG                                                                                                                                                      2011            ≥40            3,430

  Soni and colleagues, 2017 \[[@pmed.1002903.ref015]\]              India                             Community/population   Single-lead ECG (AliveCor)                                                                                                                                       2016--2017      ≥50            1,947

  Li and colleagues, 2015 \[[@pmed.1002903.ref017]\]                China                             Community/population   12-lead ECG                                                                                                                                                      2006--2011      ≥60            3,922

  Smyth and colleagues, 2016 \[[@pmed.1002903.ref018]\]             Ireland                           General practice       Pulse palpation (confirmed with 12-lead ECG)                                                                                                                     2014            ≥60            7,262

  Chao and colleagues, 2017 \[[@pmed.1002903.ref019]\]              Taiwan,\                          Pharmacy               Modified blood pressure device (Microlife WatchBP Office AFIB)                                                                                                   2015--2016      ≥60            2,672
                                                                    SAFE-Taiwan                                                                                                                                                                                                                                              

  Kvist and colleagues, 2017 \[[@pmed.1002903.ref020]\]             Denmark,\                         Community/population   Single-lead ECG (Lead-II during Cardiac-CT scan)                                                                                                                 2015--2016      65--74         1,318
                                                                    DANCAVAS                                                                                                                                                                                                                                                 

  Kaasenbrood and colleagues, 2016 \[[@pmed.1002903.ref021]\]       the Netherlands                   General practice       Single-lead ECG (MyDiagnostick)                                                                                                                                  2013            ≥65            2,557

  Lowres and colleagues, 2014 \[[@pmed.1002903.ref022]\]            Australia,\                       Pharmacy               Single-lead ECG (AliveCor)                                                                                                                                       2012--2013      ≥65            1,000
                                                                    SEARCH-AF                                                                                                                                                                                                                                                

  Sandhu and colleagues, 2016 \[[@pmed.1002903.ref023]\]            Canada,\                          Pharmacy               Single-lead ECG (HeartCheck, CardioComm)                                                                                                                         2014--2015      ≥65            1,145
                                                                    PIAAF-Pharmacy                                                                                                                                                                                                                                           

  Quinn and colleagues, 2018 \[[@pmed.1002903.ref024]\]             Canada,\                          General practice       Single-lead ECG (HeartCheck, CardioComm); modified blood pressure device (Microlife WatchBP Home A); and pulse palpation (confirmed with 12-lead ECG ± holter)   2016--2017      ≥65            2,054
                                                                    PIAAF-Family Practice                                                                                                                                                                                                                                    

  González Blanco and colleagues, 2017 \[[@pmed.1002903.ref025]\]   Spain,\                           General practice       Pulse palpation (confirmed with 12-lead ECG)                                                                                                                     2015--2016      ≥65            7,063
                                                                    DOFA                                                                                                                                                                                                                                                     

  Fitzmaurice and colleagues, 2007 \[[@pmed.1002903.ref026]\]       England,\                         General practice       12-lead ECG                                                                                                                                                      2001--2003      ≥65            2,357
                                                                    SAFE (systematic screening arm)                                                                                                                                                                                                                          

  Orchard and colleagues, 2018 \[[@pmed.1002903.ref027]\]           Australia,\                       General practice       Single-lead ECG (AliveCor)                                                                                                                                       2016--2017      ≥65            1,574
                                                                    AF-SMART                                                                                                                                                                                                                                                 

  Keen and colleagues, 2017 \[[@pmed.1002903.ref028]\]              United States                     Outpatient clinic      Single-lead ECG (AliveCor)                                                                                                                                       2016--2017      ≥65            2,732

  Wang and colleagues, 2017 \[[@pmed.1002903.ref029]\]              China                             Community/population   Single-lead ECG (AliveCor)                                                                                                                                       2017--2018      ≥65            4,421
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AF-SMART, atrial fibrillation screen management and guideline recommended therapy; DANCAVAS, Danish Cardiovascular Screening trial; DOFA, Detección Oportunista de Fibrilación Auricular en Atención Primaria Study; ECG, electrocardiogram; OFRECE, Observación de FibRilacion auricular y Enfermedad Coronaria en España; PIAAF-Pharmacy, Program for the identification of 'actionable' atrial fibrillation in the pharmacy setting; PIAAF-Family Practice, Program for the identification of 'actionable' atrial fibrillation in family practice; SAFE, screening for atrial fibrillation in the elderly; SAFE-Taiwan, screen of atrial fibrillation events in Taiwan; SEARCH-AF, Screening education and recognition in community pharmacies of atrial fibrillation.

New AF cases {#sec016}
------------

From the pooled data (*n* = 19 studies), 1,539 new cases of AF were identified from 141,220 participants screened. Limiting the results to people ≥65 years, 1,162 new cases of AF were identified from 74,104 participants screened. Absolute numbers of new AF identified were greatest within the range of 70--74 years ([Fig 2](#pmed.1002903.g002){ref-type="fig"}). The pooled yield of screening was greater in males across all age strata and increased in both men and women with increasing age ([Fig 3](#pmed.1002903.g003){ref-type="fig"}).

![Total numbers of new AF by sex.\
AF, atrial fibrillation.](pmed.1002903.g002){#pmed.1002903.g002}

![AF pooled yield by sex.\
AF, atrial fibrillation.](pmed.1002903.g003){#pmed.1002903.g003}

AF detection rate {#sec017}
-----------------

The inclusion of sex, age group, and cohort improved the fit of the random effects logistic regression model. The variables of setting, method, region, country, urban/rural, era screened, and screen age eligibility did not appear to influence the results. The final model was adjusted for age group and sex, and incorporated 18/19 studies (*n* = 138,663) for which data on total numbers screened were stratified by both age and sex \[[@pmed.1002903.ref011]--[@pmed.1002903.ref020],[@pmed.1002903.ref022]--[@pmed.1002903.ref029]\]. The study-level random effect estimate was 0.2320 (SE = 0.0889), indicating a heterogeneous sample.

The detection rate for cases of new AF identified through screening increased progressively with increasing age, as presented in the summary estimates ([Fig 4](#pmed.1002903.g004){ref-type="fig"}). Below age 60 years yield was 0.34%, increasing to 2.73% for ages 85 years and over. For screening people ≥65 years (as per guideline recommendations), the detection rate of new AF was 1.44% (95% CI, 1.13%--1.82%), compared with only 0.41% (95% CI, 0.31%--0.53%) for people aged \<65 years (rate ratio = 3.57, 95% CI, 3.10--4.10) ([Fig 5](#pmed.1002903.g005){ref-type="fig"}).

![AF detection rate (adjusted for age and sex).\
Summary estimates are calculated from the 18/19 studies that provided both gender and age for total numbers screened. AF, atrial fibrillation.](pmed.1002903.g004){#pmed.1002903.g004}

![AF detection rate for \<65 years and 65+ years.\
Summary estimates are calculated from the 18/19 studies that provided both gender and age for total numbers screened. AF, atrial fibrillation.](pmed.1002903.g005){#pmed.1002903.g005}

Stroke risk profile {#sec018}
-------------------

CHA~2~DS~2~-VASc scores were available for 1,369 new AF cases, collected at the time of screening, from 18/19 studies \[[@pmed.1002903.ref011]--[@pmed.1002903.ref024],[@pmed.1002903.ref026]--[@pmed.1002903.ref029]\]. As expected, mean CHA~2~DS~2~-VASc scores increased progressively with age, with step increases at ages 65 and 75 years ([Table 2](#pmed.1002903.t002){ref-type="table"}). CHA~2~DS~2~-VASc results appeared to be influenced by a country/cohort effect, with the highest CHA~2~DS~2~-VASc means (\>3.0) observed in Germany, Hong Kong, and America and the lowest (\<2.0) in India. The results did not appear to be influenced by setting, method, urban/rural, era screened, or screen age eligibility.

10.1371/journal.pmed.1002903.t002

###### Stroke risk profile of new AF cases (*n* = 1,369).

![](pmed.1002903.t002){#pmed.1002903.t002g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Age group,\   Number,\   CHA~2~DS~2~-VASc,\                                   ≥1 non-age/sex stroke risk factor,\   Guideline Recommendation[^†^](#t002fn002){ref-type="table-fn"}          
  years         *n*        mean[\*](#t002fn001){ref-type="table-fn"} (95% CI)   percent of age group                                                                                          
  ------------- ---------- ---------------------------------------------------- ------------------------------------- ---------------------------------------------------------------- ------ ------
  \<60          251        1.1 (0.7--1.5)                                       46                                    54                                                               19     27

  60--64        125        1.4 (1.2--1.6)                                       54                                    45.5                                                             32     22.5

  65--69        223        2.5 (2.2--2.8)                                       65                                    0                                                                35     65

  70--74        240        2.7 (2.4--2.9)                                       69                                    0                                                                32.5   67.5

  75--79        228        3.8 (3.4--4.1)                                       76                                    0                                                                0      100

  80--84        151        3.8 (3.4--4.2)                                       75                                    0                                                                0      100

  85+           151        3.9 (3.6--4.4)                                       77                                    0                                                                0      100
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Least square means.

^†^Recommendation according to the 2016 ESC AF guidelines.

Abbreviations: AF, atrial fibrillation; CHA~2~DS~2~-VASc score, (congestive heart failure/left ventricular dysfunction, high blood pressure, age \>75 years, diabetes, stroke/transient ischaemic attack/thromboembolism, vascular disease \[coronary artery disease, myocardial infarction, peripheral artery disease, aortic plaque\], age 65--74 years, sex category female); ESC, European Society of Cardiology; OAC, oral-anticoagulation.

When considering only 'non-age and non-sex' factors of the CHA~2~DS~2~-VASc score, 72% (712/993) of new AF ≥65 years had at least one additional stroke risk factor (comorbidity) other than age or sex ([Table 2](#pmed.1002903.t002){ref-type="table"}). The number with comorbidities was lower in age groups 65--69 and 70--74 years (65% and 69%, respectively); however, it was \>75% in all three age strata over 75 years.

Above age 65 years, the clear majority (84%) of screen-detected new AF was eligible for OAC with a Class-1 recommendation, according to the 2016 ESC guidelines ([Table 2](#pmed.1002903.t002){ref-type="table"}) \[[@pmed.1002903.ref003]\]. For people aged ≥75 years, 100% had a Class-1 recommendation because of age alone. In the age range 65--74 years, 66% received a Class-1 recommendation, and the remaining 34% had a recommendation to consider OAC ([Table 2](#pmed.1002903.t002){ref-type="table"}). In contrast, for those \<65 years, only 26% received a Class-1 recommendation, 23% had a recommendation to consider OAC, and half (51%) had a recommendation to not prescribe OAC ([Table 2](#pmed.1002903.t002){ref-type="table"}).

NNS {#sec019}
---

When screening people ≥65 years, the NNS to identify one new AF is 69, rising to 83 to identify one treatable new AF (i.e., those with a Class-1 OAC recommendation). A progressive increase was observed in both NNS to identify one new AF and NNS-Rx as the age group decreased ([Table 3](#pmed.1002903.t003){ref-type="table"}). Specifically, there was a large jump noted between age 65--69 to 60--64 years, in which the NNS-Rx rose steeply from 211 to 926, and a further increase to 1,089 for people aged \<60 years ([Table 3](#pmed.1002903.t003){ref-type="table"}).

10.1371/journal.pmed.1002903.t003

###### NNS.

![](pmed.1002903.t003){#pmed.1002903.t003g}

  ------------------------------------------------------------------------------------------------------
  Age group, years   NNS to identify\   NNS to identify\
                     1 new AF (*n*)     1 treatable new AF (*n*)[^‡^](#t003fn001){ref-type="table-fn"}
  ------------------ ------------------ ----------------------------------------------------------------
  \<60               294                1,089

  60--64             208                926

  65--69             137                211

  70--74             92                 136

  75--79             67                 67

  80--84             53                 53

  85+                37                 37
  ------------------------------------------------------------------------------------------------------

^‡^Newly identified AF with a Class-1 recommendation to prescribe OAC.

Abbreviations: AF, atrial fibrillation; NNS, number needed to screen; OAC, oral anticoagulation.

Discussion {#sec020}
==========

To our knowledge, this is the first study to show the actual yield of screen-detected AF and estimated stroke risk by age group, in very large numbers. Our data show that both yield and stroke risk are very sensitive to age, and the estimated stroke risk profile of new cases is high. When screening ≥65 years, the detection rate of new AF cases is 1.44% (95% CI, 1.13%--1.82%), and 84% of new AF cases have a Class-1 recommendation for OAC prophylaxis. Of note, under the 2016 Canadian AF Guidelines, all people aged ≥65 years receive an OAC recommendation based on age alone \[[@pmed.1002903.ref034]\]. The high stroke risk profile is not solely due to age and sex, as 72% of new cases aged ≥65 years have at least one additional CHA~2~DS~2~-VASc stroke risk factor (comorbidity) other than age or sex. As expected, with increasing age there is a corresponding continuous increase in the detection rate of new AF, mean CHA~2~DS~2~-VASc scores, and additional CHA~2~DS~2~-VASc stroke risk factors. The yield of screening was higher in men across all age groups, even though larger numbers of women were screened.

The detection rate of 1.44% for screening people ≥65 years is comparable to the result of 1.4%, determined from a systematic review of AF screening in 2013 \[[@pmed.1002903.ref035]\]. Both of these results are based on single time point screening and, as such, may be an underestimate of undetected AF, as some cases of paroxysmal AF may be missed. Intermittent or continuous screening over two weeks or longer will identify additional cases of paroxysmal AF, leading to a larger yield \[[@pmed.1002903.ref036]--[@pmed.1002903.ref038]\]. Indeed, only one sixth of new AF cases were detected at baseline ECG testing in the STROKESTOP trial, with the remainder detected during the subsequent two weeks of intermittent screening \[[@pmed.1002903.ref036]\]. The REHEARSE-AF study detected 3.8% with new AF by 1--2 ECGs per week over 1 year, although in that study, 1.8% of patients screened for eligibility by a single ECG had new AF detected \[[@pmed.1002903.ref039]\]. With two weeks of ambulatory ECG monitoring using an adhesive patch in the mSToPS study, 5.1% were detected with new AF \[[@pmed.1002903.ref038]\]. Although additional new AF cases are identified and the cost-effectiveness of intermittent screening has been demonstrated in a targeted population of 75-year-olds, intensive screening is more expensive, and stroke risk is lower for the most intensive screening programs (e.g., implanted cardiac monitors) \[[@pmed.1002903.ref040]\]. Therefore, intensive screening is not currently recommended for a generalised population \[[@pmed.1002903.ref041]\]. For this reason, this review focused solely on single time point screening, as it corresponds with clinical practice and is well suited for opportunistic screening according to guideline recommendations.

For implementation of opportunistic screening, our review indicates that the choice of screening setting and the methodology/device chosen to screen (i.e., pulse palpation, single-lead ECG, 12-lead ECG, or modified blood pressure machine) do not influence the detection rate. Therefore, decisions on how to implement screening can be tailored to available local or national resources, practice preference, the requirements of the health system, and the population to be screened. Decisions around developing a screening program also critically require consideration of the pathway to treatment, as 84% of new AF identified (aged ≥65 years) will require a consultation for consideration of OAC prescription.

Our data do not support screening a general population younger than 65 years, as the yield is low, and only 26% of new AF cases would receive a Class-1 recommendation to treat with OAC. Even to consider screening people aged 60--64, the NNS-Rx increases markedly to 926, compared with 211 for ages 65 to 69 years. For the population below 60 years, to identify one treatable person requires screening 1,089 people. Screening people younger than 65 may be appropriate in targeted populations (e.g., poststroke or in those with additional stroke risk factors), as both yield and stroke risk profile are likely to be higher, in which case the NNS-Rx would reduce significantly \[[@pmed.1002903.ref042],[@pmed.1002903.ref043]\].

The NNS data will be very important to determine precise estimates of cost-effectiveness. To date, health-economic analyses from many countries, based on a similar yield of new AF, have all demonstrated the likely cost-effectiveness of AF screening based on quality-adjusted life years gained and strokes avoided \[[@pmed.1002903.ref008],[@pmed.1002903.ref022],[@pmed.1002903.ref041],[@pmed.1002903.ref044]--[@pmed.1002903.ref046]\]. Cost-effectiveness is sensitive to OAC prescription rates and improves as OAC prescription rates increase \[[@pmed.1002903.ref022]\]. Given the recent trend of increased guideline-based prescription rates from 48% to 78.6% noted in the United Kingdom since the introduction of non-vitamin K antagonist OACs \[[@pmed.1002903.ref047]\], guideline-based screening of people ≥65 years, assuming a yield of 1.44%, is likely to be more cost-effective than some previously published estimates. However, cost-effectiveness calculations will also need to consider the possible influence of increased bleeding risk and the associated costs, including hospitalisations related to treatment with OAC for those with screen-detected AF \[[@pmed.1002903.ref048]\].

Furthermore, it is widely acknowledged there are no published outcome data (stroke and death) for screen-detected AF \[[@pmed.1002903.ref006],[@pmed.1002903.ref049]\]. In response to this, large screening studies with these endpoints are currently underway (e.g., ClinicalTrials.gov Identifiers NCT02743416 \[STROKESTOP II\] and NCT01593553). Once these and similar studies in the planning stages report, the outcome data can be combined with data from this review to calculate the number needed to treat to more precisely inform cost-effectiveness analyses and policy decisions on screening, based on the age distribution of the specific population to be screened. It appears that screening for AF in a general population is likely to be cost-effective if screening is commenced at age 65, in line with current international guidelines. However, actual cost-effectiveness will depend on the age distribution of the population to be screened as well as stroke rates in each stratum of the new AF cases discovered. Our estimates of likely yield of both AF cases and proportion of cases with an elevated calculated stroke risk enable organisations responsible for healthcare delivery to determine the best age cutoffs to suit their own budgets. For example, some organisations may decide on setting an age threshold of 70 or even 75 years, accepting a trade-off in missed opportunities to prevent strokes.

Limitations {#sec021}
-----------

The heterogeneity between the included studies was high. We do not have sufficient data on the sociodemographic variables of the populations screened, or possible ascertainment biases, to explain the variance in the samples. As a logistic regression approach was chosen, we were unable to assess funnel plot asymmetry; however, the rigorous methods for identification of relevant studies will likely reduce the chance of publication bias. The detection rate of unknown AF could also be inflated in a minority of studies, as self-knowledge/recall of past AF history may be inaccurate, and studies performed in areas with reduced access to medical services may have lesser rates of previous AF diagnoses. Furthermore, the data reported in this review cannot take into account what proportion of new AF would have been detected, albeit with some delay, without screening. Few of the included studies included a control population, but in the large SAFE trial, the detection rate of new AF in practices screening people ≥65 years was 1.63% per annum, 1.04% per annum in control practices, and 1.0% in 1 year in the control group of REHEARSE-AF \[[@pmed.1002903.ref026],[@pmed.1002903.ref039]\].

Conclusions {#sec022}
-----------

People detected with new AF through screening are at elevated calculated stroke risk: above age 65, the majority are eligible for and would benefit from OAC to prevent stroke, and \>70% have at least one additional stroke risk factor other than age or sex. Screening for AF in people aged ≥65 years identifies new AF in 1.44% of those screened. The detection rate was not influenced by the screening method, recruitment setting, country, or year screened. The detection rate of new AF by screening rises progressively with age, with a male predominance in all age strata. One treatable new AF will be identified for every 83 people screened in people aged ≥65 years. Our data show that the yield and stroke risk profile of new AF are sensitive to age, so the NNS-Rx is dependent on the age distribution of the population to be screened; this information is essential for precise calculations of cost-effectiveness of different age cutoffs for screening. Screening for AF in a general population is likely to be cost-effective if screening is commenced at age 65, in line with current international guidelines. However, actual cost-effectiveness will depend on the age distribution of the population to be screened, as well as stroke rates in each age stratum of the new AF cases discovered.
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AF

:   atrial fibrillation

ECG

:   electrocardiogram

ESC

:   European Society of Cardiology

NNS

:   number needed to screen

NNS-Rx

:   NNS to identify one treatable new AF case

OAC

:   oral anticoagulation

SAFE

:   screening for atrial fibrillation in the elderly
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